Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Renal Cell 13Kidney Neoplasms 4Uterine Cervical Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Clear-cell metastatic renal cell carcinoma 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced Renal Cell Carcinoma (RCC) 1Advanced Non-small Cell Lung Cancer 1

Interventions

lutetium Lu 177 dotatate 12Specimen Handling 6Magnetic Resonance Spectroscopy 6cabozantinib 5Everolimus 5pembrolizumab 4Nivolumab 4olaparib 3lenvatinib 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1surufatinib 1repotrectinib 1peposertib 1pazopanib 1entrectinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Axitinib × 90 days × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡